Merck KGaA inks xevinapant licensing deal in head, neck cancer

Seekingalpha2021-03-01

Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143). Under the terms of agreement, ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

naan
2021-03-02
naan
Super
- 2461fbaf:
  不错
handee
2021-03-01
handee
?????
Janicetxy
2021-03-01
Janicetxy
Pls help to comment. Thanks!
- 紫霞少女:
  commented
- Szezy:
  commented
Kenngaroo
2021-03-01
Kenngaroo
nice
pkycme
2021-03-01
pkycme
Lol
Loveytan
2021-03-01
Loveytan
Lol
- pkycme:
  Lol

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1188492560?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-03-01 17:49","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1188492560","market":"us","top_or_hot":-1,"title":"Merck KGaA inks xevinapant licensing deal in head, neck cancer","media":"Seekingalpha","content":"<div>\n<p>Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143).\nUnder the terms of agreement, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3667428-merck-kgaa-inks-xevinapant-licensing-deal-in-head-neck-cancer\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck KGaA inks xevinapant licensing deal in head, neck cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck KGaA inks xevinapant licensing deal in head, neck cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-01 17:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3667428-merck-kgaa-inks-xevinapant-licensing-deal-in-head-neck-cancer><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143).\nUnder the terms of agreement, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3667428-merck-kgaa-inks-xevinapant-licensing-deal-in-head-neck-cancer\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MKKGY","symbol_name":"Merck KGaA","start_time":0,"source_url":"https://seekingalpha.com/news/3667428-merck-kgaa-inks-xevinapant-licensing-deal-in-head-neck-cancer","article_id":"1188492560","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188492560","pubTimestamp":1614592156,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, fo","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MKKGY":"Merck KGaA","MKGAF":"Merck KGaA"},"translate_title":"默沙东KGaA公司签署xevinapant头颈部癌症许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MKGAF":0.9,"MKKGY":0.9},"content_text":"Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143).\nUnder the terms of agreement, Merck KGaA, gains exclusive rights to develop and commercialize xevinapant worldwide, including in the U.S.\nDebiopharm will receive €188M in upfront payments and up to €710M in milestones, as well as royalty payments.\nMerck KGaA will co-fund with Debiopharm the ongoing Phase III TrilynX study, to evaluate the efficacy and safety of xevinapant vs. placebo when added to definitive chemoradiotherapy (CRT) in cisplatin-eligible patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).\nMerck KGaA will also initiate a second global Phase III study to evaluate xevinapant in patients with LA SCCHN who are unable to tolerate high-dose cisplatin in combination with radiotherapy.\nThe agreement also includes development rights for preclinical follow-on compounds to xevinapant.\nThe transaction is expected to close in early Q2.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":362287640,"gmtCreate":1614642926180,"gmtModify":1703479191167,"author":{"id":"3574400316429410","authorId":"3574400316429410","name":"naan","avatar":"https://static.tigerbbs.com/5846811c3194d2eaeac65a7165552bc1","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3574400316429410","authorIdStr":"3574400316429410"},"htmlText":"Super","listText":"Super","text":"Super","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/362287640","repostId":1188492560,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3700486,"gmtCreate":1614726143971,"gmtModify":1614726143971,"authorId":69262229036892,"author":{"id":69262229036892,"idStr":"69262229036892","authorId":69262229036892,"name":"2461fbaf","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":362287640,"type":1,"supId":0,"prevId":0,"content":"不错","text":"不错","html":"不错"}],"langContent":"EN"},{"id":362371870,"gmtCreate":1614602828690,"gmtModify":1703478706697,"author":{"id":"3567590916259475","authorId":"3567590916259475","name":"handee","avatar":"https://static.tigerbbs.com/a96d69a3ab43a08b0f24f51486d6254c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3567590916259475","authorIdStr":"3567590916259475"},"htmlText":"?????","listText":"?????","text":"?????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/362371870","repostId":1188492560,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":362313511,"gmtCreate":1614595933433,"gmtModify":1703478619748,"author":{"id":"3567160842587234","authorId":"3567160842587234","name":"Janicetxy","avatar":"https://static.tigerbbs.com/63b856bdd08debeda5ded66d11e6ed08","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3567160842587234","authorIdStr":"3567160842587234"},"htmlText":"Pls help to comment. Thanks!","listText":"Pls help to comment. Thanks!","text":"Pls help to comment. Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/362313511","repostId":1188492560,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3688642,"gmtCreate":1614598295601,"gmtModify":1635759942282,"authorId":3569880573857204,"author":{"id":3569880573857204,"idStr":"3569880573857204","authorId":3569880573857204,"name":"紫霞少女","avatar":"https://static.tigerbbs.com/dbc9aeadf774aaa9cf89d89d3a832f3c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":362313511,"type":1,"supId":0,"prevId":0,"content":"commented","text":"commented","html":"commented"},{"id":3690414,"gmtCreate":1614611727298,"gmtModify":1635759875787,"authorId":3560239999320656,"author":{"id":3560239999320656,"idStr":"3560239999320656","authorId":3560239999320656,"name":"Szezy","avatar":"https://static.tigerbbs.com/e62d3cd4ad29125966f9b2b36810bc9a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":362313511,"type":1,"supId":0,"prevId":0,"content":"commented","text":"commented","html":"commented"}],"langContent":"EN"},{"id":362319434,"gmtCreate":1614595842028,"gmtModify":1703478618214,"author":{"id":"3575005933062903","authorId":"3575005933062903","name":"Kenngaroo","avatar":"https://static.tigerbbs.com/64f060389d919cadcc673831998e0fa2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575005933062903","authorIdStr":"3575005933062903"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/362319434","repostId":1188492560,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":362336155,"gmtCreate":1614595170877,"gmtModify":1703478609173,"author":{"id":"3572041120390941","authorId":"3572041120390941","name":"pkycme","avatar":"https://static.tigerbbs.com/2c8abf6e02924915f7b31ba778563bcc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3572041120390941","authorIdStr":"3572041120390941"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/362336155","repostId":1188492560,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":362338930,"gmtCreate":1614595092020,"gmtModify":1703478607464,"author":{"id":"3572158983231416","authorId":"3572158983231416","name":"Loveytan","avatar":"https://static.tigerbbs.com/34c80695455223ae87f77cb5adb10f85","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3572158983231416","authorIdStr":"3572158983231416"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/362338930","repostId":1188492560,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3688272,"gmtCreate":1614595179149,"gmtModify":1635759959152,"authorId":3572041120390941,"author":{"id":3572041120390941,"idStr":"3572041120390941","authorId":3572041120390941,"name":"pkycme","avatar":"https://static.tigerbbs.com/2c8abf6e02924915f7b31ba778563bcc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":362338930,"type":1,"supId":0,"prevId":0,"content":"<u>Lol</u>","text":"<u>Lol</u>","html":"<u>Lol</u>"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":28,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188492560"}